TEVA

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.27
Percentage change 1.58	%

Peers: JNJ ABBV AZN MRK GSK LLY PFE BMY NVS SNY

| Held by: IEFA EFA EFV IXUS EIS PPH SPDW IDEV IVLU DBEF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.85	Insider Own	0.00%	Shs Outstand	1.13B	Perf Week	-6.53%
Market Cap	19.66B	Forward P/E	6.12	EPS next Y	2.83	Insider Trans	-	Shs Float	1.13B	Perf Month	-18.41%
Income	-961.00M	PEG	-	EPS next Q	0.51	Inst Own	57.18%	Short Float	1.39%	Perf Quarter	-6.07%
Sales	16.81B	P/S	1.17	EPS this Y	4.44%	Inst Trans	2.21%	Short Ratio	1.40	Perf Half Y	3.90%
Book/sh	5.35	P/B	3.24	EPS next Y	8.86%	ROA	-2.29%	Short Interest	15.80M	Perf Year	41.12%
Cash/sh	2.93	P/C	5.92	EPS next 5Y	5.66%	ROE	-14.76%	52W Range	11.83 - 22.80	Perf YTD	-21.37%
Dividend Est.	-	P/FCF	7.18	EPS past 5Y	26.63%	ROI	-4.22%	52W High	-23.99%	Beta	0.82
Dividend TTM	-	Quick Ratio	0.61	Sales past 5Y	-1.44%	Gross Margin	49.97%	52W Low	46.49%	ATR (14)	0.78
Dividend Ex-Date	Nov 27, 2017	Current Ratio	0.89	EPS Y/Y TTM	57.37%	Oper. Margin	22.45%	RSI (14)	29.58	Volatility	4.62% 3.28%
Employees	37226	Debt/Eq	3.18	Sales Y/Y TTM	9.85%	Profit Margin	-5.72%	Recom	1.67	Target Price	24.71
Option/Short	Yes / Yes	LT Debt/Eq	2.75	EPS Q/Q	-647.09%	Payout	-	Rel Volume	1.66	Prev Close	17.06
Sales Surprise	2.00%	EPS Surprise	0.38%	Sales Q/Q	13.40%	Earnings	Jan 29 BMO	Avg Volume	11.29M	Price	17.33
SMA20	-14.93%	SMA50	-11.68%	SMA200	-1.93%	Trades		Volume	1,207,878	Change	1.58%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-24	Upgrade	Argus	Hold → Buy	$20
Mar-08-24	Upgrade	JP Morgan	Underweight → Neutral	$14
Feb-12-24	Upgrade	Piper Sandler	Neutral → Overweight	$12 → $19
Jan-23-24	Upgrade	Jefferies	Hold → Buy	$10 → $14
Jan-03-24	Upgrade	Piper Sandler	Underweight → Neutral	$8 → $12
Dec-18-23	Initiated	HSBC Securities	Buy	$13
Nov-27-23	Upgrade	UBS	Neutral → Buy	$11 → $13
Jul-06-23	Upgrade	UBS	Sell → Neutral	$7 → $8
May-25-23	Initiated	Morgan Stanley	Equal-Weight	$10
May-18-23	Upgrade	Evercore ISI	In-line → Outperform
Jan-19-23	Downgrade	Jefferies	Buy → Hold	$10 → $12
Nov-14-22	Downgrade	JP Morgan	Neutral → Underweight	$11 → $10
Nov-04-22	Downgrade	UBS	Neutral → Sell
Oct-21-22	Resumed	Jefferies	Buy	$10
Aug-05-22	Upgrade	BofA Securities	Neutral → Buy	$10 → $13
Jun-14-22	Resumed	UBS	Neutral	$10
May-17-22	Upgrade	BofA Securities	Underperform → Neutral	$9
May-04-22	Downgrade	Piper Sandler	Neutral → Underweight	$11 → $7
Apr-05-22	Upgrade	Barclays	Equal Weight → Overweight	$11 → $13
Mar-25-22	Upgrade	Bernstein	Mkt Perform → Outperform	$11

Show Previous Ratings

Jan-31-25 08:00AM	This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry (Investor's Business Daily)
02:14AM	Teva Pharmaceutical Industries Ltd (TEVA) Q4 2024 Earnings Call Highlights: Strong Revenue ... (GuruFocus.com)
Jan-30-25 07:05AM	Why Teva Pharmaceuticals (TEVA) Crashed on Wednesday? (Insider Monkey)
Jan-29-25 03:37PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research) -13.89%
02:26PM	Why Teva Pharmaceutical Stock Is Sinking Today (Motley Fool)
02:15PM	Loading…
02:15PM	Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript (Motley Fool)
01:18PM	Teva Stock Dives 14%. Why Its CEO Says It's A Victim. (Investor's Business Daily)
01:18PM	Teva Stock Dives 14%. 'We're Victims Of Our Own Success,' Says CEO. (Investor's Business Daily)
12:43PM	Trump Media's Truth.Fi, T-Mobile, Teva: Market Minute (Yahoo Finance Video)
11:39AM	VF Corp, Corning, Teva: Trending stocks (Yahoo Finance Video)
09:32AM	Teva Pharmaceutical Posts Lower Revenue. Stock Slips. (Investor's Business Daily)
09:30AM	Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
07:00AM	Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth (GlobeNewswire)
Jan-27-25 06:00AM	Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi and Simponi Aria (golimumab) (GlobeNewswire)
Jan-23-25 07:44AM	FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis cases (Pharmaceutical Technology)
08:20AM	Loading…
Jan-18-25 08:20AM	Ozempic, Xtandi among next 15 drugs selected for U.S. price talks (TipRanks)
Jan-17-25 09:46AM	Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations (Yahoo Finance)
Jan-13-25 11:55AM	How Teva Pharmaceuticals is thinking about Trump's return: CEO (Yahoo Finance Video)
01:00AM	Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea (aflibercept) in major parts of Europe and in Israel (GlobeNewswire)
Jan-10-25 08:30AM	Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI (eculizumab-aagh) in the United States (GlobeNewswire)
Jan-09-25 12:31PM	Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical (Benzinga)
Jan-08-25 04:10PM	IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva (Investor's Business Daily)
Jan-03-25 10:47AM	Why Teva Pharmaceuticals Industries Ltd. (TEVA) Crashed Yesterday (Insider Monkey)
Dec-28-24 09:27AM	Teva Pharmaceutical Industries Ltd (TEVA) Ends Trading Week Defying Market Bloodbath (Insider Monkey)
Dec-24-24 04:51AM	Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2025 (Motley Fool)
04:05AM	Why Teva Pharmaceuticals Industries (TEVA) Skyrocketed? (Insider Monkey)
Dec-23-24 04:30PM	Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-24 07:58AM	Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory (Insider Monkey)
Dec-20-24 04:30PM	Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025 (GlobeNewswire)
04:51AM	My Top 10 Portfolio Holdings for 2025 (Motley Fool)
07:45AM	Loading…
Dec-19-24 07:45AM	Teva price target raised to $28 from $26 at UBS (TipRanks)
Dec-18-24 02:50PM	Jim Cramer on Teva Pharmaceutical Industries (TEVA): A Game-Changer for Intractable Disease Treatments? (Insider Monkey)
07:08AM	Fed decision looms, Nvidia looks to rebound: Yahoo Finance (Yahoo Finance Video)
06:39AM	Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength? (Zacks)
05:26AM	Sanofi and Tevas duvakitug meets primary endpoints in Phase IIb trial (Clinical Trials Arena)
Dec-17-24 09:47PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research) +26.47%
04:36PM	Teva and Sanofi jump on experimental bowel disease drug success (Yahoo Finance Video)
04:10PM	Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug (Investor's Business Daily)
01:20PM	Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's (Investopedia)
12:00PM	Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations (GuruFocus.com)
11:55AM	Teva Catapults 22%, Hitting A Five-Year High, After Scoring A Win With Sanofi-Tied Drug (Investor's Business Daily)
11:51AM	Teva, Cloudflare, Sanofi: Trending Tickers (Yahoo Finance Video)
11:51AM	Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment (The Wall Street Journal)
10:37AM	Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug (Investor's Business Daily)
09:17AM	Teva Stock Soars on Early Bowel Disease Drug Data (Barrons.com)
09:17AM	Teva Shares Soar on Early Bowel Disease Drug Data (Barrons.com)
09:16AM	Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? (Benzinga)
07:30AM	Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease (GlobeNewswire)
Dec-11-24 08:00AM	Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients (GlobeNewswire)
Dec-05-24 06:00PM	Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan (GlobeNewswire)
05:13AM	Teva reports positive outcomes from episodic migraine trial in young patients (Clinical Trials Arena)
Dec-04-24 02:00AM	Teva Presents Positive Efficacy and Safety Data of AJOVY (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial (GlobeNewswire)
Nov-25-24 06:00PM	Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-21-24 02:47AM	Teva Pharmaceutical (TEVA): The Global Leader in Affordable Medicine Under $25 (Insider Monkey)
Nov-15-24 09:09AM	Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory (Insider Monkey)
Nov-08-24 04:30PM	Teva to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
09:40AM	Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now? (Zacks)
Nov-07-24 02:06AM	Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Highlights: Strong Revenue ... (GuruFocus.com)
Nov-06-24 04:06PM	'This Is A New Teva,' Says CEO. But Investors Don't Seem To Believe. (Investor's Business Daily) -7.14%
02:41PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
02:08PM	Teva Retreats, Sacrificing A Breakout, Despite Its Third-Quarter Beat And Raise (Investor's Business Daily)
11:30AM	Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript (Motley Fool)
10:08AM	Teva's Explosive Q3 Results: Pivot to Growth Strategy Shocks Investors with Record Revenue Surge (GuruFocus.com)
09:30AM	Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:57AM	Teva Pharmaceutical Flashes A Buy Signal On Upbeat Third-Quarter Report (Investor's Business Daily)
07:00AM	Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS (GlobeNewswire)
Nov-04-24 12:00PM	Teva Pharmaceutical Industries (TEVA) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Nov-01-24 03:05PM	Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition (GlobeNewswire)
03:00PM	Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY (risperidone) (GlobeNewswire)
09:15AM	Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
06:40AM	EC fines Teva $502m over multiple sclerosis treatment Copaxone practices (Pharmaceutical Technology)
Oct-31-24 02:49PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
09:26AM	Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns (The Wall Street Journal)
08:46AM	EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug (Associated Press Finance)
07:30AM	Teva Statement on European Commission Decision; Company to Appeal (GlobeNewswire)
Oct-25-24 09:55AM	Wall Street Analysts Predict a 25.1% Upside in Teva Pharmaceutical Industries (TEVA): Here's What You Should Know (Zacks)
Oct-23-24 09:40AM	Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year? (Zacks)
Oct-22-24 06:35PM	Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory (Insider Monkey)
09:20AM	Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
07:00AM	Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara (ustekinumab) (GlobeNewswire)
Oct-17-24 11:07AM	Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug (Benzinga)
Oct-11-24 12:49PM	Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes (Benzinga)
Oct-10-24 05:19PM	Teva Pharmaceuticals to Pay $450 Million to Settle Kickback Allegations (The Wall Street Journal)
Oct-09-24 03:30PM	Teva Pharmaceutical Industries Ltd (TEVA) Q2 2024 Earnings Call Highlights: Strong Revenue ... (GuruFocus.com)
Oct-08-24 07:00AM	Teva Prolia (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA (GlobeNewswire)
Oct-07-24 09:40AM	Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now? (Zacks)
09:40AM	Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-04-24 06:33AM	Teva and mAbxience partner to develop biosimilar candidate for oncology (Pharmaceutical Technology)
Oct-03-24 08:30AM	Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate (GlobeNewswire)
Oct-01-24 08:29AM	Teva Announces Launch of the First and Only Generic Version of Sandostatin LAR Depot (octreotide acetate for injectable suspension), in the U.S. (GlobeNewswire)
03:38AM	Why Are Analysts Bullish On Teva Pharmaceutical Industries Limited (TEVA) Right Now? (Insider Monkey)
Sep-30-24 04:30PM	Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024 (GlobeNewswire)
01:01PM	Invesco EQV European Equity Fund Bolsters Position in Teva Pharmaceutical with a 1. ... (GuruFocus.com)
Sep-24-24 08:45AM	As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse (GlobeNewswire)
Sep-23-24 10:33AM	Teva touts safety profile of once monthly schizophrenia therapy (Pharmaceutical Technology)
01:00AM	Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia (GlobeNewswire)
Sep-21-24 04:15AM	Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia (GlobeNewswire)
04:10AM	New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY (risperidone) Extended-Release Injectable Suspension from Perseris (RBP-7000) (GlobeNewswire)
Sep-11-24 04:30PM	Teva to Present at the Bank of America 2024 Global Healthcare Conference (GlobeNewswire)

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MIGNONE ROBERTO	Director	Dec 20 '24	Sale	22.01	286,000	6,294,031	695,000	Dec 26 04:02 PM
Bridger Management, LLC (1)	Shareholder	Dec 20 '24	Proposed Sale	21.31	286,000	6,094,660		Dec 20 07:03 PM
Fox Christine	EVP, Head of U.S. Commercial	Nov 20 '24	Sale	16.87	19,388	327,085	44,104	Nov 21 04:04 PM
Fox Christine	Officer	Nov 20 '24	Proposed Sale	16.87	19,388	327,085		Nov 20 11:39 AM
Daniell Richard	Exec. VP, European Commercial	Aug 12 '24	Sale	17.30	98,943	1,711,447	0	Aug 13 04:09 PM
Grant Angus	EVP, Business Development	Aug 09 '24	Sale	17.28	4,065	70,243	8,848	Aug 13 04:06 PM
Hughes Eric A	See "Remarks"	Aug 09 '24	Sale	17.38	45,060	782,972	0	Aug 13 04:02 PM
Daniell Richard	Officer	Aug 12 '24	Proposed Sale	17.30	98,943	1,711,444		Aug 12 04:09 PM
Hughes Eric A	Officer	Aug 09 '24	Proposed Sale	17.38	45,060	782,974		Aug 12 03:59 PM
Grant Angus	Officer	Aug 09 '24	Proposed Sale	17.28	4,065	70,243		Aug 09 03:59 PM
Hughes Eric A	See "Remarks"	Aug 01 '24	Sale	17.25	24,537	423,280	45,060	Aug 05 07:35 AM
Hughes Eric A	Officer	Aug 01 '24	Proposed Sale	17.25	24,537	423,281		Aug 01 04:00 PM
MIGNONE ROBERTO	Director	Jun 18 '24	Sale	17.03	519,000	8,838,570	981,000	Jun 21 04:05 PM
Weiss Amir	Chief Accounting Officer	May 15 '24	Sale	16.80	15,500	260,417	17,814	May 17 07:41 AM
Weiss Amir	Chief Accounting Officer	May 16 '24	Sale	16.65	12,635	210,377	5,179	May 17 07:41 AM
Conway Vikki L	See "Remarks"	May 13 '24	Sale	16.74	15,219	254,807	0	May 15 08:36 AM
Kalif Eliyahu Sharon	EVP, Chief Financial Officer	Mar 06 '24	Sale	13.52	77,550	1,048,119	203,691	Mar 07 04:27 PM
Daniell Richard	Exec. VP, European Commercial	Mar 05 '24	Sale	13.52	48,629	657,240	69,770	Mar 07 04:20 PM
Conway Vikki L	See "Remarks"	Mar 05 '24	Sale	13.52	1,427	19,286	15,219	Mar 07 04:16 PM
Sabag Mark	EVP, International Markets	Mar 05 '24	Sale	13.52	100,000	1,352,090	382,590	Mar 07 04:12 PM
Conway Vikki L	See "Remarks"	Mar 04 '24	Sale	13.37	3,532	47,234	6,617	Mar 05 04:39 PM
Francis Richard D	President and CEO	Mar 04 '24	Sale	13.34	31,061	414,270	123,295	Mar 05 04:27 PM
Daniell Richard	Exec. VP, European Commercial	Mar 04 '24	Sale	13.34	95,762	1,277,207	69,770	Mar 05 04:21 PM
Hughes Eric A	See "Remarks"	Mar 04 '24	Sale	13.34	8,045	107,299	16,855	Mar 05 04:16 PM
Drape Eric	Executive VP Global Operations	Feb 28 '24	Sale	13.12	9,815	128,734	9,701	Mar 01 06:45 AM
Daniell Richard	Exec. VP, European Commercial	Feb 28 '24	Sale	13.12	20,599	270,176	69,770	Mar 01 06:43 AM
Conway Vikki L	See "Remarks"	Feb 28 '24	Sale	13.12	1,366	17,916	2,928	Mar 01 06:40 AM
Drape Eric	Executive VP Global Operations	Feb 16 '24	Sale	13.05	173,261	2,261,905	1	Feb 21 07:37 AM
Francis Richard D	President and CEO	Feb 15 '24	Sale	13.15	74,530	980,174	87,125	Feb 20 07:42 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Teva- Pharmaceutical Industries Ltd. ADR

Upgrade your FINVIZ experience